|
1
|
Dhomen NS, Mariadason J, Tebbutt N and
Scott AM: Therapeutic targeting of the epidermal growth factor
receptor in human cancer. Crit Rev Oncog. 17:31–50. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Baselga J and Arteaga CL: Critical update
and emerging trends in epidermal growth factor receptor targeting
in cancer. J Clin Oncol. 23:2445–2459. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rimawi MF, Shetty PB, Weiss HL, Schiff R,
Osborne CK, Chamness GC and Elledge RM: Epidermal growth factor
receptor expression in breast cancer association with biologic
phenotype and clinical outcomes. Cancer. 116:1234–1242. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shigematsu H and Gazdar AF: Somatic
mutations of epidermal growth factor receptor signaling pathway in
lung cancers. Int J Cancer. 118:257–262. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gan HK, Kaye AH and Luwor RB: The EGFRvIII
variant in glioblastoma multiforme. J Clin Neurosci. 16:748–754.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bronte G, Terrasi M, Rizzo S, Sivestris N,
Ficorella C, Cajozzo M, Di Gaudio F, Gulotta G, Siragusa S, Gebbia
N and Russo A: EGFR genomic alterations in cancer: Prognostic and
predictive values. Front Biosci (Elite Ed). 3:879–887.
2011.PubMed/NCBI
|
|
7
|
Sharma MR and Schilsky RL: GI cancers in
2010: New standards and a predictive biomarker for adjuvant
therapy. Nat Rev Clin Oncol. 8:70–72. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abramson V and Arteaga CL: New strategies
in HER2-overexpressing breast cancer: Many combinations of targeted
drugs available. Clin Cancer Res. 17:952–958. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Seshacharyulu P, Ponnusamy MP, Haridas D,
Jain M, Ganti AK and Batra SK: Targeting the EGFR signaling pathway
in cancer therapy. Expert Opin Ther Targets. 16:15–31. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pandya K, Meeke K, Clementz AG, Rogowski
A, Roberts J, Miele L, Albain KS and Osipo C: Targeting both Notch
and ErbB-2 signalling pathways is required for prevention of
ErbB-2-positive breast tumour recurrence. Br J Cancer. 105:796–806.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Konecny GE, Pegram MD, Venkatesan N, Finn
R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, et
al: Activity of the dual kinase inhibitor lapatinib (GW572016)
against HER-2-overexpressing and trastuzumab-treated breast cancer
cells. Cancer Res. 66:1630–1639. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wainberg ZA, Anghel A, Desai AJ, Ayala R,
Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ and Finn RS:
Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively
inhibits HER2-amplified human gastric cancer cells and is
synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res.
16:1509–1519. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Satoh T, Xu RH, Chung HC, Sun GP, Doi T,
Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, et al: Lapatinib plus
paclitaxel versus paclitaxel alone in the second-line treatment of
HER2-amplified advanced gastric cancer in Asian populations:
TyTAN-a randomized, phase III study. J Clin Oncol. 30:2039–2049.
2014. View Article : Google Scholar
|
|
14
|
Shimoyama S: Unraveling trastuzumab and
lapatinib inefficiency in gastric cancer: Future steps (Review).
Mol Clin Oncol. 2:175–181. 2014.PubMed/NCBI
|
|
15
|
Cenciarelli C, Marei HE, Zonfrillo M,
Pierimarchi P, Paldino E, Casalbore P, Felsani A, Vescovi AL, Maira
G and Mangiola A: PDGF receptor alpha inhibition induces apoptosis
in glioblastoma cancer stem cells refractory to anti-Notch and
anti-EGFR treatment. Mol Cancer. 13:2472014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen T, Yang K, Yu J, Meng W, Yuan D, Bi
F, Liu F, Liu J, Dai B, Chen X, et al: Identification and expansion
of cancer stem cells in tumor tissues and peripheral blood derived
from gastric adenocarcinoma patients. Cell Res. 22:248–258. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang J, Zhang Y, Chuai S, Wang Z, Zheng
D, Xu F, Zhang Y, Li C, Liang Y and Chen Z: Trastuzumab (herceptin)
targets gastric cancer stem cells characterized by CD90 phenotype.
Oncogene. 31:671–682. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu G, Shen J, Ou Yang X, Sasahara M and Su
X: Cancer stem cells: The ‘heartbeat’ of gastric cancer. J
Gastroenterol. 48:781–797. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim TH and Shivdasani RA: Notch signaling
in stomach epithelial stem cell homeostasis. J Exp Med.
208:677–688. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Takebe N, Nguyen D and Yang SX: Targeting
notch signaling pathway in cancer: Clinical development advances
and challenges. Pharmacol Ther. 141:140–149. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cenciarelli C, Marei HE, Zonfrillo M,
Casalbore P, Felsani A, Giannetti S, Trevisi G, Althani A and
Mangiola A: The interference of Notch1 target Hes1 affects cell
growth, differentiation and invasiveness of glioblastoma stem cells
through modulation of multiple oncogenic targets. Oncotarge.
8:17873–17886. 2017.
|
|
22
|
Liu ZH, Dai XM and Du B: Hes1: A key role
in stemness, metastasis and multidrug resistance. Cancer Biol Ther.
16:353–359. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yin B, Zeng Y, Liu G, Wang X, Wang P and
Song Y: MAGE-A3 is highly expressed in a cancer stem cell-like side
population of bladder cancer cells. Int J Clin Exp Pathol.
7:2934–2941. 2014.PubMed/NCBI
|
|
25
|
Liu J, Ma L, Xu J, Liu C, Zhang J, Liu J,
Chen R and Zhou Y: Spheroid body-forming cells in the human gastric
cancer cell line MKN-45 possess cancer stem cell properties. Int J
Oncol. 42:453–459. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee J, Kotliarova S, Kotliarov Y, Li A, Su
Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, et al:
Tumor stem cells derived from glioblastomas cultured in bFGF and
EGF more closely mirror the phenotype and genotype of primary
tumors than do serum-cultured cell lines. Cancer Cell. 9:391–403.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radio-resistance by preferential activation of the
DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li LC, Wang DL, Wu YZ, Nian WQ, Wu ZJ, Li
Y, Ma HW and Shao JH: Gastric tumor-initiating CD44+ cells and
epithelial-mesenchymal transition are inhibited by γ-secretase
inhibitor DAPT. Oncol Lett. 10:3293–3299. 2015.PubMed/NCBI
|
|
29
|
Yamaguchi H, Chang SS, Hsu JL and Hung MC:
Signaling cross-talk in the resistance to HER family receptor
targeted therapy. Oncogene. 33:1073–1081. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang P, Shu B, Xu Y, Zhu J, Liu J, Zhou Z,
Chen L, Zhao J, Liu X, Qi S, et al: Basic fibroblast growth factor
reduces scar by inhibiting the differentiation of epidermal stem
cells to myofibroblasts via the Notch1/Jagged1 pathway. Stem Cell
Res Ther. 8:1142017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Aster JC and Blacklow SC: Targeting the
Notch pathway: Twists and turns on the road to rational
therapeutics. J Clin Oncol. 30:2418–2420. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takebe N, Nguyen D and Yang SX: Targeting
notch signaling pathway in cancer: Clinical development advances
and challenges. Pharmacol Ther. 141:140–149. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu ZH, Dai XM and Du B: Hes1: A key role
in stemness, metastasis and multidrug resistance. Cancer Biol Ther.
16:353–359. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hynes NE and MacDonald G: ErbB receptors
and signaling pathways in cancer. Curr Opin Cell Biol. 21:177–184.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Burgess AW: EGFR family: Structure
physiology signalling and therapeutic targets. Growth Factors.
26:263–274. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Arasada RR, Amann JM, Rahman MA, Huppert
SS and Carbone DP: EGFR blockade enriches for lung cancer stem-like
cells through Notch3-dependent signaling. Cancer Res. 74:5572–5584.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xie M, Zhang L, He CS, Xu F, Liu JL, Hu
ZH, Zhao LP and Tian Y: Activation of Notch-1 enhances
epithelial-mesenchymal transition in gefitinib-acquired resistant
lung cancer cells. J Cell Biochem. 113:1501–1513. 2012.PubMed/NCBI
|
|
39
|
Morishita A, Gong J and Masaki T:
Targeting receptor tyrosine kinases in gastric cancer. World J
Gastroenterol. 20:4536–4545. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang B, Lindley LE, Fernandez-Vega V,
Rieger ME, Sims AH and Briegel KJ: The T box transcription factor
TBX2 promotes epithelial-mesenchymal transition and invasion of
normal and malignant breast epithelial cells. PLoS One.
7:e413552012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Houthuijzen JM, Daenen LG, Roodhart JM and
Voest EE: The role of mesenchymal stem cells in anti-cancer drug
resistance and tumour progression. Br J Cancer. 106:1901–1906.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chockalingam S and Ghosh SS: Amelioration
of cancer stem cells in macrophage colony stimulating
factor-expressing U87MG-human glioblastoma upon 5-fluorouracil
therapy. PLoS One. 8:e838772013. View Article : Google Scholar : PubMed/NCBI
|
